Bone Density for Men — Body Handbook

Screening · §102

Bone Density for Men

Osteoporosis isn't only a women's problem — close to 40% of low-impact breaks happen in men, and when an older man breaks a hip, roughly one in three is dead within the year. The check for it is a ten-minute bone-density scan; the standard treatment is a generic tablet that costs less than coffee for a year. Most men who'd benefit get neither, because nobody told them they were the right kind of man for it.

Decide · Yearly Evidence Moderate Chapter Screening

The reason to bother is single-event prevention. A broken hip after 70 is one of the worst things that can land on an older man — high one-year death rate, slow road back to walking, often a one-way trip into a nursing home. The screen is cheap, the standard treatment is cheap, and the effect is large: fracture risk roughly halves. There's no real catch — this is one of the rare preventive moves that asks almost nothing of your week and pays back a catastrophe avoided.

Men's bones don't fail the way women's do — they fail later, and worse. There's no abrupt drop the way menopause delivers; instead, peak bone in your late twenties slowly drains out at roughly half a percent a year from age 50 onward, and the men whose drift is fastest tend to be the ones with one of a small list of accelerators: low testosterone, daily prednisone for an autoimmune condition or COPD, heavy alcohol, smoking, long stretches of inactivity, hormone therapy for prostate cancer Watts et al. 2012. By the time something snaps from a fall that wouldn't have broken you at 40, the bone underneath has been thinning for decades, quietly.

The thing that pushes men's bones along isn't only testosterone, despite the cultural assumption. Both testosterone and the small amount of estradiol men make matter, and estradiol is actually the stronger predictor of how your bones hold up. This matters for a practical reason later — a treatment that raises testosterone won't necessarily save your hip.

What we actually know — and what's been missed

About one in eight men worldwide has osteoporosis on a bone-density scan; a man past 50 has roughly a one in seven lifetime chance of a low-impact fracture, and around four in ten of all fragility fractures happen in men, not women. The catch is that only about one in ten men with osteoporosis ever gets the diagnosis or the treatment for it. Most quietly accumulate small spine fractures they never notice until their pants start to ride higher and their belt notch moves in.

The treatment side is on firmer ground than the screening side. Trials of bisphosphonates and denosumab in men show fracture or bone-density gains that match what was seen in the original female trials Orwoll et al. 2000 Boonen et al. 2012 Orwoll et al. 2012. The argument that lingers is over screening — specialist societies say screen older men, the US Preventive Services Task Force says the screen-vs-no-screen trial hasn't been done in men so they can't say either way Watts et al. 2012 USPSTF 2018. The practical effect of that disagreement is that your primary-care doctor may not bring it up. You may have to.

What happens if you keep ignoring it

The thing you're trying to avoid is one specific morning. You're 74. You stand up from the couch, your foot catches the corner of the rug, you put a hand out to steady yourself, your hip hits the floor. You're not knocked out. You can't get up. The pain isn't dramatic — it's locked-in. The ambulance comes, the orthopaedic surgeon comes, the hip gets pinned or replaced; you wake up two days later on a ward, full of lines, and the year of your life that begins in that bed is mostly not yours anymore.

That morning ends a lot of older men. Across the cohort studies, one-year mortality after a hip fracture in men runs roughly a quarter to over a third, with the steepest danger in the first three months — the death rate in those months runs about eight times higher than for matched men who didn't break a hip Haentjens et al. 2010. Of the men who do survive, only about two in three get back to walking the way they used to; one in five ends up in long-term institutional care. At every age, men do worse after a hip fracture than women do.

The slower version isn't the one ambulance arrives for. It's the spine fractures you don't notice as they happen — a vertebra collapses by a few millimetres while you carry a suitcase up the stairs or sneeze hard. Stack a few of those over a decade and your shirts stop fitting the way they used to, your pants ride up because your torso got shorter, your wife mentions you look stooped, the round of golf leaves your mid-back aching in a way it didn't last year, and the deep breath you used to take doesn't fill the way it used to either. Your grandkid points it out when you bend down. None of it killed you, but the man in the photo from your fiftieth birthday is taller and straighter than the one in the mirror, and the gap is mostly skeleton.

When to scan, and what happens after

The cleanest version of the rule: every man should get a DEXA scan at 70, and earlier than that — somewhere between 50 and 69 — if any of a short list of accelerators apply to you. That's what the specialist guideline says Watts et al. 2012. The mainstream primary-care framework says wait for stronger trial evidence before screening men routinely USPSTF 2018, which is why this often won't get offered to you and you'll need to ask.

Get a DEXA scan if you are:

A man aged 70 or older — no other criteria needed.
A man aged 50–69 with any of: a prior break from a small fall, a parent who broke a hip, low body weight (under ~155 lb / 70 kg), heavy smoker, more than two or three drinks a day, on prednisone or a similar steroid at 5 mg or more for over three months, on hormone-blocking treatment for prostate cancer, low testosterone, an overactive thyroid or parathyroid.
Any age, if you've already had a fragility fracture (one from a fall from standing height or less) — you don't need the scan to know you should treat.

What the result means: the scan gives you a T-score. A T-score at or below -2.5 is osteoporosis. Between -1 and -2.5 is osteopenia — thin, not yet broken-territory. Your doctor will also run a FRAX probability; in the US, treatment is generally recommended if FRAX puts your 10-year hip-fracture probability over 3% or your major-osteoporotic-fracture probability over 20%.

If you treat: a weekly oral generic (alendronate or risedronate) is the usual first move; a yearly IV infusion of zoledronic acid is the alternative when you can't tolerate the pill ritual. Either one is taken for five years before reassessing.

Either way, the lifestyle stack underneath: twice-weekly heavy resistance training, daily calcium 1,000–1,200 mg (food first), vitamin D 800–1,000 IU/day, protein at least 1.0 g/kg of body weight per day, alcohol under three drinks a day, no smoking, and a sober look at the rugs and the stairs in your house.

Where the treatments need care

The scan itself has no real downside — radiation is a tiny fraction of a chest x-ray, and there's no needle. The medications are where to pay attention.

Bisphosphonate tablets (alendronate, risedronate) need to be taken on an empty stomach with a full glass of water and you have to stay upright for thirty minutes after — otherwise they can irritate the esophagus. Don't take them if your kidneys are working at below about a third of normal.
Jaw and femur problems are real but rare: dental osteonecrosis and atypical thigh-bone fractures both run around one per ten thousand treatment-years, and both rise the longer you stay on. Most people are reassessed at five years; not everyone needs to keep going. Tell your dentist before any major work.
Denosumab (Prolia, every six months) cannot be stopped cold turkey — when you come off, you must be bridged onto a bisphosphonate, or you'll lose bone fast and risk a cluster of new spine fractures inside a year.
Romosozumab (Evenity) carries a black-box warning for heart attack and stroke risk — it is not for men who've had either in the past year Lewiecki et al. 2018.
Testosterone replacement is not a bone-density treatment. A 2024 trial in middle-aged and older men with low testosterone and cardiovascular risk found testosterone actually increased clinical fracture risk versus placebo, against everyone's expectations Snyder et al. 2024. Treat the bone problem as a bone problem.

What most guides get wrong

"This is a women's disease." It's not. About four in ten low-impact fractures happen in men, and men do worse afterwards at every age Haentjens et al. 2010. The frame is the single biggest reason men with osteoporosis don't get diagnosed or treated.

"Walking is enough." Walking maintains very little bone after you're already loading it daily — though strapping on a weighted pack, the practice called rucking, loads the hip and spine enough to start counting. The signal for bone in older men comes from heavy stuff — barbell work, weighted squats and deadlifts done with intent, jumps and impact — done twice a week under supervision if you've never lifted before Harding et al. 2020.

"Testosterone will protect my bones." It raises bone density on the scan, but in the largest trial that measured actual fractures, it raised them Snyder et al. 2024. If you have genuine clinical low testosterone with symptoms, replace it for those reasons; don't expect it to do the osteoporosis job.

"I haven't broken anything, so I'm fine." About one in eight older men is walking around with a vertebral fracture they don't know about. The first noticeable break is often the hip — by which point you're already in the bad-outcome category.

"Calcium pills handle the gap." Food calcium first — dairy, leafy greens, sardines, fortified products — with a small supplement to top up only if you can't reach 1,000 mg from food. Big isolated calcium boluses don't add fracture protection and can constipate you and seed kidney stones.

Where this falls apart in real life

The fracture that doesn't trigger treatment. The biggest hole isn't the first scan — it's the visit to the orthopaedic surgeon after the first break. A man who's just had a wrist fixed is at high risk for the next, much worse, fracture; the prescription for the bone medication is supposed to follow him out of the hospital and rarely does. Roughly nine out of ten men leave that visit without anyone starting them on treatment. If you've ever broken a bone from a small fall as an adult, ask explicitly whether you should be on bisphosphonates — don't assume someone already decided.

The weekly pill that drifts. Most men who start oral alendronate are no longer taking it a year later. The ritual is fussy — empty stomach, full glass of water, stay upright thirty minutes — and once it slips a week, it usually slips for good. If that sounds like you, ask about the yearly IV infusion instead; one appointment and you're set for twelve months.

Treating the bone, not the fall. Most hip fractures happen in a fall. A man on the best possible bone medication who's also on six other prescriptions, can't see well at night, has a throw rug at the top of the stairs, and gets dizzy when he stands up is still going to break. Walk the house with someone who'll be honest — the rug, the bathmat, the lighting, the dose of the sleep aid, the glasses prescription — they all count.

What changes when you do this

The payoff is mostly an event that doesn't happen. You won't notice the difference at week two of taking the tablet — your bones don't feel different, your knee still aches the same. What you'll notice is the negative: the morning that didn't end with an ambulance, the holiday with the grandkids you spent on your feet, the second decade of retirement that looks like the first.

The visible payoff arrives slower and quieter. Five years in, you're the same height you were at sixty; ten years in, the friends who didn't bother are an inch and a half shorter than you and bent at the shoulders. Twenty years in, you're the one still walking into the diner under your own steam while three of the eight men you graduated high school with are gone or living somewhere they can't leave. None of this is dramatic, but the absence of the catastrophe is the whole point.

Adjacent things worth looking at

Resistance training for older men. The lifting protocol that helps bones is the same one that holds onto muscle, balance, and reflexes — those are what stop you falling in the first place.
Vitamin D adequacy. Cheap to test, cheap to fix; matters here and in a dozen other places.
Testosterone replacement therapy. If you have genuine low-testosterone symptoms it has its own case to make, but treat it as a separate decision from your bones — don't fold them together.
Prostate cancer and androgen-deprivation therapy. If you're on or about to start ADT, your bones become a much more urgent topic, and earlier; that's a specific situation worth its own conversation with your oncologist.
Fall prevention. Tai chi, balance training, polypharmacy review, home setup. The medication side of bone health gets all the attention; the floor-side gets the fractures.

Related in the handbook

Helps

— Loading bone is one of the few things that builds it back — lifting belongs in any bone plan.
— Weighted walking loads the hips and spine — a gentle way to stress bone into staying dense.
— Vitamin D is part of keeping bone strong — worth checking alongside a density scan.
— A few milligrams of boron a day cuts urinary calcium loss — a minor, cheap add-on to the proven bone essentials, not a substitute.

Diagnosis

— The scan men need for bone density is a DEXA — and it can report muscle and visceral fat in the same sitting.
— A low T-score on your scan is the entry point to this protocol: workup, risk-sizing, and the right drug first.

— Low testosterone is a leading cause of thinning bone in men — if your scan is low, getting your level checked is part of the workup.
— Keeping bone density up isn't just calcium and vitamin D; K2 helps put that calcium into bone rather than into your arteries.

Substance and claimed effects

This entry covers the screening and management of low bone mineral density (BMD) and osteoporosis in adult men, with the action span running from getting a baseline dual-energy x-ray absorptiometry (DXA) scan at the right age, through FRAX-based 10-year fracture-risk estimation, to pharmacological treatment when indicated and the lifestyle scaffolding (resistance training, adequate vitamin D and calcium, fall prevention, alcohol moderation) that supports it. The substance is best understood as a defensive screen-and-treat behaviour rather than a positive intervention: the dimensions it moves are longevity (large — hip fracture carries roughly one-in-three one-year mortality in older men, and treatment more than halves vertebral fracture risk), beauty_cumulative (small — vertebral fractures cause permanent height loss and kyphosis), health_short_term (small — fewer fractures mean preserved mobility), and mood (small — fewer post-fracture depressive episodes, lower fear-of-falling burden). The brief named four downstream consequences (detection, fracture prevention, mobility, post-fracture mortality); all four are covered.

Evidence by addressing question

mechanism

Adult bone is continually remodelled by osteoclasts (resorbing) and osteoblasts (forming). Peak BMD in men is reached around age 25–30; from roughly age 50 a slow loss of about 0.5–1% per year begins, accelerated by hypogonadism, glucocorticoid exposure, chronic inflammation, smoking, heavy alcohol intake, and immobilisation. Men start from a higher peak BMD and larger bone size than women and do not undergo the abrupt menopausal oestrogen withdrawal that drives the female trajectory — which is why fragility fractures arrive about a decade later in men but, when they do arrive, occur in a frailer host with worse outcomes Cawthon et al. 2016.

Sex steroids are central. Both testosterone and (via aromatisation) oestradiol regulate male bone — and oestradiol is the stronger predictor of male BMD and fracture in cohort analyses. Up to half of male osteoporosis cases are secondary, most commonly to hypogonadism, glucocorticoids, and alcohol excess Watts et al. 2012. Glucocorticoid effects are mechanistically distinct: prednisone-equivalent doses ≥5 mg/day suppress osteoblast function and accelerate osteoclast survival within weeks, producing rapid trabecular bone loss and a five-fold rise in vertebral fracture risk at ≥7.5 mg/day.

evidence

Epidemiology. Approximately 12% of men globally have osteoporosis by BMD criteria; men aged 50 and older carry a roughly 13% lifetime fracture risk, and about 40% of all fragility fractures occur in men. Only about 10% of men with osteoporosis receive osteoporosis-directed treatment after a fragility fracture — an order of magnitude below post-fracture treatment rates in women, despite worse outcomes.

Detection. Among 5,958 community-dwelling older men in the MrOS cohort with evaluable lateral spine films, 11.6% had one or more radiographic vertebral fractures and 7.5% had moderate-to-severe fractures — the great majority undiagnosed clinically Orwoll et al. 2005. Historical height loss is a useful trigger for vertebral imaging.

Mortality. The Haentjens meta-analysis (24 cohorts; >500,000 person-years) found the relative hazard for all-cause mortality in the first three months after hip fracture was 7.95 in men versus 5.75 in women, with excess mortality persisting for years and being higher in men at every age Haentjens et al. 2010. One-year mortality after hip fracture in older men runs roughly 25–37% across cohorts; roughly one third of survivors do not return to prior mobility, and 10–20% require long-term institutional care.

Pharmacological fracture prevention in men, by agent:

Alendronate (10 mg daily, 2 years, n=241): vertebral fracture incidence 0.8% vs 7.1% on placebo (p=0.02); BMD gains at spine and hip matched those seen in women's trials Orwoll et al. 2000.
Zoledronic acid (5 mg IV yearly, 2 years, n=1,199 men with primary or hypogonadism-related osteoporosis): morphometric vertebral fracture risk reduced by 67% (1.6% vs 4.9%; HR 0.33) Boonen et al. 2012.
Denosumab (60 mg subcutaneous every 6 months, 24 months, ADAMO trial, n=242): lumbar spine BMD +5.7% vs +0.9% placebo; FDA-approved 2012 for men with osteoporosis at high fracture risk on the basis of BMD parity with the female pivotal trials, not a powered fracture endpoint Orwoll et al. 2012.
Romosozumab (210 mg subcutaneous monthly, 12 months, BRIDGE trial, n=245): lumbar spine BMD +12.1% vs +1.2% placebo. A numerical excess of cardiovascular serious adverse events (4.9% vs 2.5%) drives a black-box warning Lewiecki et al. 2018.
Teriparatide (anabolic PTH analogue, 20 µg subcutaneous daily): approved for men with primary or hypogonadal osteoporosis at high fracture risk; BMD gains and mechanism mirror those in the female pivotal trials.

Exercise. The LIFTMOR-M semi-randomised trial in middle-aged and older men with low BMD (n=93, 8 months twice-weekly supervised high-intensity resistance and impact training, HiRIT) found improvements in medial femoral neck cortical thickness and preservation of distal radius and tibia bone strength — a mechanistic signal that loading-based training, not just weight-bearing aerobics, has skeletal effect in men Harding et al. 2020.

protocol

Whom to screen. The 2012 Endocrine Society guideline recommends central DXA of spine and hip in all men aged ≥70, and in men 50–69 with risk factors (prior adult fragility fracture, parental hip fracture, body weight <70 kg, smoking, alcohol >3 units/day, glucocorticoid use ≥5 mg prednisone-equivalent for ≥3 months, androgen deprivation therapy, hypogonadism, primary hyperparathyroidism, hyperthyroidism, COPD, malabsorption, GnRH agonists) Watts et al. 2012. The USPSTF (2018) judged evidence insufficient to recommend for or against screening in men, citing absence of RCTs of screening itself (rather than treatment) in a male population USPSTF 2018. The Bone Health and Osteoporosis Foundation and AACE positions align with the Endocrine Society.

Diagnostic thresholds. WHO T-score criteria (men ≥50, using a young-adult male reference): T ≤ −2.5 at lumbar spine, total hip, or femoral neck = osteoporosis. Any adult-life fragility fracture at hip or spine is independently diagnostic regardless of T-score. Add a 10-year FRAX probability calculated with femoral neck BMD; US treatment thresholds are typically major osteoporotic fracture ≥20% or hip fracture ≥3%.

First-line pharmacotherapy. Oral alendronate or risedronate weekly for most; annual IV zoledronic acid when oral intolerance, adherence, or upper-GI contraindications are issues; denosumab every 6 months when bisphosphonates are unsuitable (CKD eGFR <30 ml/min). For very high baseline risk (multiple vertebral fractures, T ≤ −3.0 with prior fracture), an anabolic agent (teriparatide or romosozumab) first for 12–24 months, then antiresorptive consolidation. Treat any documented secondary cause concurrently (testosterone replacement in confirmed hypogonadism; vitamin D repletion; glucocorticoid taper if feasible).

Lifestyle scaffolding. Daily calcium intake 1,000–1,200 mg (food first, supplement to fill the gap); vitamin D 800–1,000 IU/day with target serum 25(OH)D ≥30 ng/mL; protein intake ≥1.0–1.2 g/kg/day; weekly high-intensity resistance training plus impact loading; alcohol <3 units/day; smoking cessation; fall-prevention review (footwear, lighting, throw rugs, polypharmacy audit).

contraindications

The screening step has no meaningful contraindication. Pharmacotherapy carries the standard agent-specific cautions:

Bisphosphonates: avoid in eGFR <30–35 ml/min; oral forms require upright posture for 30 min post-dose (esophageal injury risk); rare osteonecrosis of the jaw (~1 per 10,000 patient-years on oral therapy; ~1% in high-dose oncology use) and atypical femoral fractures (~1 per 10,000 patient-years, rising with treatment duration beyond 5 years).
Denosumab: rebound vertebral fracture risk if discontinued without antiresorptive bridging — must not be stopped without a follow-on bisphosphonate.
Romosozumab: contraindicated within 12 months of MI or stroke; the BRIDGE trial showed a numerical excess of positively adjudicated cardiovascular serious events (4.9% vs 2.5%) Lewiecki et al. 2018.
Testosterone replacement in men without confirmed hypogonadism is not a bone treatment: in the TRAVERSE fracture substudy (n=5,204 middle-aged and older men with hypogonadism and cardiovascular risk), testosterone produced more clinical fractures than placebo (HR 1.43, 95% CI 1.04–1.97), against the prior BMD-based expectation Snyder et al. 2024.

misconceptions

"Osteoporosis is a women's disease." Roughly 40% of fragility fractures occur in men, and post-hip-fracture mortality is materially higher in men at every age Haentjens et al. 2010. The disease-as-female-only frame is the largest driver of undertreatment.

"Walking is enough." Walking maintains very little BMD in already-loaded bones; the LIFTMOR-M signal is for high-intensity resistance and impact, not steady-state cardio Harding et al. 2020.

"Testosterone protects against fracture." Testosterone raises BMD in hypogonadal men, but TRAVERSE found the fracture endpoint moved the wrong way Snyder et al. 2024. TRT is not an osteoporosis treatment except as part of correcting confirmed clinical hypogonadism.

"Calcium supplements close the gap." The gap is best closed with food (dairy, leafy greens, fortified products); large isolated calcium boluses may modestly raise cardiovascular event rates and produce constipation and kidney stones without adding fracture protection over dietary calcium.

"If I haven't broken anything, my bones are fine." The MrOS data show ~12% of older men have at least one radiographic vertebral fracture they don't know about; height loss of more than ~4 cm is a flag Orwoll et al. 2005.

audience

The entry is male-only by topic. Within men, three sub-populations warrant tailored guidance:

Men 70+ generally. Baseline DXA recommended without further qualification.
Men 50–69 with risk factors. Screen on risk factor presence; FRAX-then-DXA is reasonable when no fracture has occurred.
Men of any adult age on androgen deprivation therapy (e.g., prostate cancer), or on long-term glucocorticoids (≥5 mg prednisone for ≥3 months). Baseline DXA at therapy initiation, repeat at 1–2 years, low threshold for bisphosphonate or denosumab prophylaxis irrespective of T-score.

failure-modes

The post-fracture treatment gap. A fragility fracture is the strongest predictor of the next one (~2-fold within 1–2 years). Yet only ~10% of men receive osteoporosis-directed care after their first fragility fracture. Fracture liaison services close this gap and are the dominant operational lever for translating evidence into outcome.

Adherence collapse on oral bisphosphonates. Median real-world persistence on weekly alendronate is under 12 months; the dosing ritual (upright, fasted, water-only, 30 min) is the main culprit. Switching to annual zoledronic acid removes the adherence variable.

Denosumab discontinuation rebound. Stopping denosumab without a bisphosphonate bridge produces rapid BMD loss and a documented cluster of multiple vertebral fractures within 9–18 months. This is a clinician-side failure-mode but worth a patient flag.

Treating BMD without treating falls. Most hip fractures happen in a fall. A pharmacologically dense, balance-poor, polypharmacy-laden older man is still at high fracture risk. Vitamin D ≥800 IU/day in deficient older adults reduces falls modestly; structured balance work (tai chi, gait/strength programmes) reduces falls more.

practicalities

A central DXA scan in the US runs ~$100–$300 cash, often covered without copay for Medicare-eligible men with risk factors (CPT 77080); insurance coverage is uneven for men under 70 without a coded risk factor. Generic alendronate is roughly $20–$50/year. Generic zoledronic acid runs ~$100–$300 per annual infusion; denosumab is on the order of $1,500–$2,500/year list, with insurance reducing patient cost substantially. Romosozumab and teriparatide are five-figure-per-year list-price agents, typically reserved for very high fracture risk.

history

Male osteoporosis was a recognised clinical entity throughout the 20th century but research investment lagged the female trajectory by roughly a generation. The first dedicated NIH-funded male prospective cohort, MrOS, launched in 2000 (n=5,994), and remains the principal data source for natural history and fracture prediction in older men Orwoll et al. 2005. FDA approval of alendronate for men followed the Orwoll 2000 trial; zoledronic acid (2007) and denosumab (2012) followed dedicated male-specific trials; the Endocrine Society's 2012 guideline was the first major society document to consolidate screening and treatment recommendations specifically for men Watts et al. 2012.

stakes

The substance an aging man is screening against is a low-energy fracture — most commonly hip, spine, or distal radius. Hip fracture in older men carries one-year mortality of roughly 25–37%, with the steepest hazard in the first three months (relative hazard ~8 vs age-matched men without fracture) Haentjens et al. 2010. Among survivors, roughly a third do not return to their prior level of mobility; 10–20% enter long-term institutional care. Vertebral fractures, often clinically silent, accumulate as progressive height loss, kyphosis, restrictive ventilatory impairment, abdominal protrusion, and chronic mid-back pain. The decade after a first fragility fracture is the most concentrated period of downstream morbidity.

payoff

The payoff is largely the absence of a single catastrophic event. At the population level: bisphosphonate therapy in men reduces vertebral fracture incidence by approximately two-thirds Boonen et al. 2012, and prevents the cascade of immobility, deconditioning, pneumonia, delirium, and excess mortality that follows a hip fracture. The earlier the screen-and-treat decision is made — ideally before the first fracture — the larger the absolute risk reduction. At the individual level, an at-risk man who screens at 70, learns he is osteoporotic, treats for 5 years on weekly alendronate, lifts twice a week, and keeps his vitamin D and protein adequate roughly halves his next-decade fracture probability versus no intervention.

The credibility range

Optimist case

Male osteoporosis is one of the few areas in adult preventive medicine where the underlying biology, the diagnostic test, the risk calculator, and the treatments all converge on the same answer with strong evidence behind each step. DXA is cheap, fast, and reproducible. FRAX is validated in men Orwoll et al. 2005. Bisphosphonate trials in men show fracture reductions parallel to those in women Orwoll et al. 2000 Boonen et al. 2012. Hip fracture is one of the most lethal events that befall an older man, with a clean mechanistic path from low BMD to fracture to mortality Haentjens et al. 2010. Generic oral alendronate costs less per year than a tank of gas. The bottleneck is not the science; it is that ~90% of men with osteoporosis go untreated. A screen-and-treat policy applied to all men ≥70 would prevent tens of thousands of hip fractures and thousands of deaths annually in the US alone.

Skeptic case

The USPSTF's "insufficient evidence" judgment on screening men is not perverse: no large RCT has randomised men to screen-vs-no-screen and measured fracture outcomes USPSTF 2018. All male treatment trials have used BMD or surrogate fracture endpoints (alendronate's 7.1% placebo vertebral fracture rate is high because the cohort was small and enriched for risk); the male-specific fracture RCTs are smaller and shorter than their female counterparts. Bisphosphonates carry rare but real harms (osteonecrosis of the jaw, atypical femoral fracture) that scale with treatment duration. The TRAVERSE result with testosterone is a recent reminder that BMD gains do not always translate to fracture reduction Snyder et al. 2024. Vitamin D and calcium supplementation in unselected adults has not robustly reduced fracture risk in recent large trials. And the typical screening target — an asymptomatic 70-year-old man — has a 5–10-year horizon during which competing mortality (cardiovascular, neoplastic) often dominates.

Author's call

The treatment trials in men (alendronate, zoledronic acid, denosumab) are convincing for fracture reduction at the individual level; the screening framework is well-articulated by the Endocrine Society and operationally validated by fracture liaison services. The USPSTF's holdout is a screening-trial-purity objection, not a quarrel with the treatment evidence. For this entry the call is: men ≥70 should get a baseline DXA; men 50–69 with any of the named risk factors should get one; men on chronic glucocorticoids or androgen deprivation should be treated as high-risk regardless of T-score. Evidence rates 4 (well-replicated trials in men; minor gap on screening RCT). Controversy rates 2 (a real screening debate, near-consensus on treatment).

Stakeholder + incentive map

Endocrinology / metabolic bone specialty societies (Endocrine Society, AACE, BHOF, IOF) — push for broader male screening; rate-limited by primary-care adoption.
USPSTF and primary care — conservative on adding screening lines without RCT evidence specific to the screening intervention; reflects a population-medicine cost-effectiveness frame.
Pharma — generic bisphosphonates have no commercial driver; the active marketing is around denosumab (Amgen), romosozumab (Amgen/UCB), and teriparatide/abaloparatide (Lilly/Radius). All three benefit from a screening expansion.
Orthopaedic surgery — sees the fractures, often does not initiate antiresorptive therapy, hands off to primary care where the treatment gap reopens. Fracture liaison services exist to close this.
Patient community — relatively quiet; no patient-advocacy voice on the scale of women's osteoporosis advocacy. Reinforces the "women's disease" framing.
Testosterone clinics — commercial incentive to frame TRT as bone-protective; TRAVERSE complicates that pitch substantially Snyder et al. 2024.

Population variability

BMD trajectories vary by race (lower hip fracture incidence in Black and Hispanic men than in non-Hispanic White and East Asian men, even at similar BMD), body composition (lean men <70 kg are higher risk; obesity is partially protective for hip fracture but not for vertebral), and underlying physiology (androgen deprivation therapy collapses the trajectory rapidly; chronic glucocorticoid use does the same regardless of underlying disease).

FRAX is calibrated country by country; its discrimination is better for hip fracture than for major osteoporotic fracture, and it does not include falls as an input. The MrOS data demonstrate that fall propensity adds incremental fracture-prediction value over FRAX in older men — a gap the FRAXplus extension aims to close.

Younger men (≤50) with osteoporosis are nearly always secondary cases — hypogonadism, glucocorticoids, anorexia, idiopathic juvenile osteoporosis, osteogenesis imperfecta — and require an endocrine workup rather than empirical bisphosphonate therapy. This subgroup is out of the typical screening frame and into a diagnostic frame.

Knowledge gaps

No RCT has tested male osteoporosis screening (vs no screening) on hard fracture outcomes. The USPSTF's "insufficient" call rests entirely on this gap. A pragmatic cluster-randomised trial in primary care would resolve it.
The mechanism by which testosterone increases BMD but raises clinical fracture in TRAVERSE remains unclear; candidate explanations include cortical bone effects, increased activity, or chance in a single trial Snyder et al. 2024.
Romosozumab's cardiovascular signal in men is small in absolute numbers and underpowered; the long-term cardiovascular profile in male populations is unsettled Lewiecki et al. 2018.
Optimal anabolic-to-antiresorptive sequencing in very-high-risk men is mostly extrapolated from female trials.
Race-specific fracture trajectories and treatment response in non-White men are under-sampled in pivotal trials.

Scope vs brief. The brief named detection, fracture prevention, mobility, and post-fracture mortality. All four are covered: detection in evidence and protocol, prevention in protocol and payoff, mobility and post-fracture mortality in stakes. Nothing was silently dropped.

Audience scoping. Set as male-only, ages 40–59 and 60+. Younger men (under 40) are not a natural screening target — when they have osteoporosis it's almost always secondary to hypogonadism, steroids, anorexia, or rare genetic disease, and they need a workup rather than this entry's screen-and-treat frame. Flagged the under-40 case in research §3e (population variability) but kept it out of the article body.

Rating call: longevity at 4, not 5. The intervention prevents a high-lethality event (hip fracture) and the treatment evidence is solid (~67% vertebral fracture reduction with zoledronic acid), but the population-level mortality impact depends on adherence and on actually getting screened. A 5 would require dominant population-mortality bending; this clears 4 but not 5.

Rating call: evidence at 4, not 5. The male treatment RCTs are multiple and consistent, the guideline is firm, and the mechanism is unambiguous. Held at 4 because there is no screen-vs-no-screen RCT in men — the USPSTF gap is real, and inflating the evidence score would paper over it.

Rating call: controversy at 2. Real disagreement on screening (Endocrine Society vs USPSTF) but near-consensus on treatment. Not a 3 because the disagreement is procedural (trial purity) rather than foundational (no one argues treatment doesn't work in men).

Action: decide, not test or do. The reader's first move is a clinician conversation about whether the scan is right for them — the test follows that. decide captures the weighing better than test, which would imply self-directed lab work.

Cadence: yearly. The closest fit for a periodic screening cadence (DXA repeats every 1–3 years depending on result). Not once — re-scanning is part of the protocol.

Contraindications field left empty. The substance (screening + treatment decision) has no closed-vocabulary contraindication. Drug-specific cautions (esophageal disease for oral bisphosphonates, recent MI for romosozumab, low eGFR for bisphosphonates) sit inside the article's contraindications section rather than at the meta level, since they apply to specific agents and don't fit the closed token list.

TRAVERSE finding handled carefully. The 2024 fracture-substudy result that testosterone increased clinical fractures in older hypogonadal men is recent and counterintuitive. Treated it as established for the misconceptions and contraindications sections rather than burying it — but flagged in research §3f (knowledge gaps) that the mechanism is unsettled.

Separate-entry candidates worth queuing.

Androgen-deprivation therapy and bone loss — a high-risk subgroup the article points at but doesn't cover end-to-end.
Glucocorticoid-induced osteoporosis — overlaps but has its own treatment timing rules; warrants its own entry across the autoimmune and respiratory populations.
Resistance training for older adults — referenced in out-of-scope; load-bearing detail belongs in its own entry.
Fall prevention in older adults — half of fracture prevention; this entry only gestures at it.

Future cross-links to wire in once siblings exist: creatine for muscle in older men, vitamin D testing and repletion, testosterone replacement decision, prostate cancer screening, fall-prevention programs.